- Home
- ALKS
ALKS
Alkermes plc
as 07-26-2024 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 4.2B | IPO Year: | 1991 |
| Target Price: | $36.70 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.70 | EPS Growth: | 203.57 |
| 52 Week Low/High: | $22.01 - $32.88 | Next Earning Date: | 07-24-2024 |
| Revenue: | $1,507,916,000 | Revenue Growth: | 3.14% |
| Revenue Growth (this year): | -7.96% | Revenue Growth (next year): | 0.07% |
Stock Insider Trading Activity of Alkermes plc (ALKS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | ALKS | SVP, Chief Commercial Officer | Mar 18 '24 | Sell | $28.10 | 10,417 | $292,739.58 | 65,911 | SEC Form 4 |
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 23 '24 | Sell | $29.65 | 2,559 | $75,874.35 | 7,717 | SEC Form 4 |
| LAURENCIN CATO T | ALKS | Director | Feb 15 '24 | Sell | $31.85 | 2,690 | $85,676.50 | 15,169 | SEC Form 4 |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
Zacks
a day ago
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
MT Newswires
a day ago
HC Wainwright Adjusts Price Target on Alkermes to $37 From $35, Maintains Neutral Rating
MT Newswires
a day ago
Baird Adjusts Price Target on Alkermes to $38 From $37, Maintains Outperform Rating
Zacks
2 days ago
Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say
Zacks
3 days ago
Alkermes (ALKS) Lags Q2 Earnings Estimates
MT Newswires
3 days ago
Alkermes Q2 Adjusted Earnings Rise, Revenue Falls
Simply Wall St.
3 days ago
Is Alkermes plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals?
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.